Constellation Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Constellation Investments’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$1.52M	Buy	10,900 +325	+3%	+$47.7K	0.28%	75
2015 Q4	$2.02M	Buy	10,575 +25	+0.2%	+$4.37K	0.38%	61
2015 Q3	$1.65M	Buy	10,550 +775	+8%	+$141K	0.34%	67
2015 Q2	$1.77M	Buy	9,775 +450	+5%	+$77.7K	0.34%	69
2015 Q1	$1.62M	Buy	9,325 +475	+5%	+$86K	0.31%	73
2014 Q4	$1.64M	Buy	8,850 +325	+4%	+$60.2K	0.33%	66
2014 Q3	$1.41M	Sell	8,525 -25	-0.3%	-$4.11K	0.31%	72
2014 Q2	$1.34M	Sell	8,550 -50	-0.6%	-$7.89K	0.31%	72
2014 Q1	$1.31M	Buy	8,600 +475	+6%	+$75.5K	0.32%	72
2013 Q4	$1.08M	Buy	8,125 +600	+8%	+$72K	0.27%	81
2013 Q3	$874K	Buy	7,525 +475	+7%	+$52.1K	0.27%	87
2013 Q2	$650K	Buy	+7,050	New	+$679K	0.23%	99

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Constellation Investments's ALXN Position: Q1 2016 in Review

Constellation Investments increased its Alexion Pharmaceuticals (ALXN) stake by 3.1% in Q1 2016, buying an estimated $47.7K and bringing the position to 10,900 shares worth $1.52M. The position accounts for 0.28% of the portfolio, ranked #75.

Constellation Investments first reported a position in ALXN in Q2 2013 and has held it in 12 quarters since. The position peaked at $2.02M in Q4 2015. 520 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

Constellation Investments held 10,900 shares of Alexion Pharmaceuticals worth $1.52M as of Q1 2016.
Constellation Investments bought 325 Alexion Pharmaceuticals shares in Q1 2016, an estimated $47.7K.
Alexion Pharmaceuticals made up 0.28% of Constellation Investments's portfolio in Q1 2016, its #75 holding.
Constellation Investments first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
Constellation Investments's Alexion Pharmaceuticals position peaked at $2.02M in Q4 2015.
520 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Constellation Investments's 13F filing for Q1 2016, filed 28 Apr 2016.